相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis
Hyunwoo Lee et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis
Hyunwoo Lee et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Diversity of Immune Cell Types in Multiple Sclerosis and Its Animal Model: Pathological and Therapeutic Implications
Yun Cheng et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2017)
Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis
Emanuele Pravata et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Paolo A. Muraro et al.
JAMA NEUROLOGY (2017)
Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis
Emanuele Pravata et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models
Sarah Neil et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis
J. Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
George D. Kalliolias et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis
J. Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
Per Soelberg Sorensen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Novel Agents for Relapsing Forms of Multiple Sclerosis
Rebecca Straus Farber et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Dimethyl fumarate activates the prostaglandin EP2 receptor and stimulates cAMP signaling in human peripheral blood mononuclear cells
Sarah E. Fiedler et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Oxidative stress in multiple sclerosis: Central and peripheral mode of action
Kim Ohl et al.
EXPERIMENTAL NEUROLOGY (2016)
Role of Regulatory B Cells in Neuroimmunologic Disorders
Jinming Han et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2016)
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study
Laure Peyro Saint Paul et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold L. Atkins et al.
LANCET (2016)
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2016)
Hydroxycitric acid ameliorates inflammation and oxidative stress in mouse models of multiple sclerosis
Mahdi Goudarzvand et al.
NEURAL REGENERATION RESEARCH (2016)
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Ludwig Kappos et al.
NEUROLOGY (2016)
Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse
Ye Zhang et al.
NEURON (2016)
New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis
Bozena Adamczyk et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2016)
Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?
Maha M. Bakhuraysah et al.
STEM CELL RESEARCH & THERAPY (2016)
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
Harald Hegen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis
Sunny Malhotra et al.
BRAIN (2015)
Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity
Reiner Kunze et al.
EXPERIMENTAL NEUROLOGY (2015)
The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity
Andrew L. Croxford et al.
IMMUNITY (2015)
The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: Interleukin-17A and interleukin-17F serum levels
Zohreh Babaloo et al.
IMMUNOLOGY LETTERS (2015)
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study
Emmanuelle Le Page et al.
JOURNAL OF NEUROLOGY (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
L. Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial
Claire M. Rice et al.
TRIALS (2015)
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes
He Huang et al.
REDOX BIOLOGY (2015)
From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development
Avraham Ben-Nun et al.
JOURNAL OF AUTOIMMUNITY (2014)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2014)
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
Aaron E. Miller et al.
LANCET NEUROLOGY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Patrick Vermersch et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Per S. Sorensen et al.
NEUROLOGY (2014)
ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY
Paul Browne et al.
NEUROLOGY (2014)
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study
Katrin Strassburger-Krogias et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
SIRT1 Activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease
Reas S. Khan et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
MitoQ a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis
Peizhong Mao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination
Thomas Skripuletz et al.
BRAIN (2013)
Disease-specific molecular events in cortical multiple sclerosis lesions
Marie Therese Fischer et al.
BRAIN (2013)
The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response
Lorenz C. Hundgeburth et al.
CLINICAL IMMUNOLOGY (2013)
Novel immunoregulatory properties of EGCG on reducing inflammation in EAE
Quanye Sun et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2013)
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies
Nicolas Molnarfi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse
Sebastian M. Fiebiger et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Ralf Gold et al.
LANCET (2013)
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj et al.
LANCET NEUROLOGY (2013)
Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned
Harold L. Atkins et al.
NEUROTHERAPEUTICS (2013)
Cortical lesion load associates with progression of disability in multiple sclerosis
Massimiliano Calabrese et al.
BRAIN (2012)
Mitochondrial changes within axons in multiple sclerosis: an update
Graham R. Campbell et al.
CURRENT OPINION IN NEUROLOGY (2012)
Identification of a microglia phenotype supportive of remyelination
Marta Olah et al.
GLIA (2012)
Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis
Jacqueline A. Quandt et al.
JOURNAL OF IMMUNOLOGY (2012)
Ferritin Stimulates Oligodendrocyte Genesis in the Adult Spinal Cord and Can Be Transferred from Macrophages to NG2 Cells In Vivo
David L. Schonberg et al.
JOURNAL OF NEUROSCIENCE (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2012)
Animal models of multiple sclerosis: the good, the bad and the bottom line
Richard M. Ransohoff
NATURE NEUROSCIENCE (2012)
Progressive multiple sclerosis: pathology and pathogenesis
Hans Lassmann et al.
NATURE REVIEWS NEUROLOGY (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation
Dimitrios Davalos et al.
NATURE COMMUNICATIONS (2012)
Disruption of central nervous system barriers in multiple sclerosis
Jorge Ivan Alvarez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Oxidative damage in multiple sclerosis lesions
Lukas Haider et al.
BRAIN (2011)
Risks and benefits of multiple sclerosis therapies: need for continual assessment?
Bernd C. Kieseier et al.
CURRENT OPINION IN NEUROLOGY (2011)
The molecular basis of neurodegeneration in multiple sclerosis
Hans Lassmann et al.
FEBS LETTERS (2011)
Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice
V. Abraira et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis
Priya Chaudhary et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
EMMPRIN: A Novel Regulator of Leukocyte Transmigration into the CNS in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Smriti M. Agrawal et al.
JOURNAL OF NEUROSCIENCE (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Ivana Nikic et al.
NATURE MEDICINE (2011)
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study
F. Sangalli et al.
NEUROLOGICAL SCIENCES (2011)
Swedish natalizumab (Tysabri) multiple sclerosis surveillance study
Fredrik Piehl et al.
NEUROLOGICAL SCIENCES (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Excess Circulating Alternatively Activated Myeloid (M2) Cells Accelerate ALS Progression While Inhibiting Experimental Autoimmune Encephalomyelitis
Ilan Vaknin et al.
PLOS ONE (2011)
Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis
Aine C. Murphy et al.
BRAIN BEHAVIOR AND IMMUNITY (2010)
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
J. M. Fletcher et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Tempol ameliorates murine viral encephalomyelitis by preserving the blood-brain barrier, reducing viral load, and lessening inflammation
Maria Heloisa Tsuhako et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
Gadofluorine M-enhanced MRI shows involvement of circumventricular organs in neuroinflammation
Eva Wuerfel et al.
JOURNAL OF NEUROINFLAMMATION (2010)
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis
Ernst-Wilhelm Radue et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. (vol 9, pg 381, 2010)
D. Wynn et al.
LANCET NEUROLOGY (2010)
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial
J. F. Lovera et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse
Darius Moharregh-Khiabani et al.
PLOS ONE (2010)
Animal models of multiple sclerosis-Potentials and limitations
Eilhard Mix et al.
PROGRESS IN NEUROBIOLOGY (2010)
Exploring the roles of CD8+ T lymphocytes in the pathogenesis of autoimmune demyelination
Trina A. Johnson et al.
SEMINARS IN IMMUNOPATHOLOGY (2010)
The Absence of the Pro-antioxidant Transcription Factor Nrf2 Exacerbates Experimental Autoimmune Encephalomyelitis
Delinda A. Johnson et al.
TOXICOLOGICAL SCIENCES (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn et al.
LANCET NEUROLOGY (2010)
Immunopathogenesis of multiple sclerosis
Michael K. Racke
ANNALS OF INDIAN ACADEMY OF NEUROLOGY (2009)
Pathogenic CD8+ T Cells in Multiple Sclerosis
Manuel A. Friese et al.
ANNALS OF NEUROLOGY (2009)
Mitochondrial changes within axons in multiple sclerosis
Don J. Mahad et al.
BRAIN (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
Complement in multiple sclerosis: its role in disease and potential as a biomarker
G. Ingram et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Axonal degeneration in multiple sclerosis: The mitochondrial hypothesis
Kimmy G. Su et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2009)
Tempol protection of spinal cord mitochondria from peroxynitrite-induced oxidative damage
Yiqin Xiong et al.
FREE RADICAL RESEARCH (2009)
Antioxidant therapy in multiple sclerosis
Abbas Mirshafiey et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2009)
Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis
Pablo Kizelsztein et al.
JOURNAL OF NEUROIMMUNOLOGY (2009)
Identification of Two Distinct Macrophage Subsets with Divergent Effects Causing either Neurotoxicity or Regeneration in the Injured Mouse Spinal Cord
Kristina A. Kigerl et al.
JOURNAL OF NEUROSCIENCE (2009)
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS
Richard A. Rudick et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Knowns and unknowns in the future of multiple sclerosis treatment
Olaf Stüve
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo
Mandy J. McGeachy et al.
NATURE IMMUNOLOGY (2009)
Memantine induces reversible neurologic impairment in patients with MS
P. Villoslada et al.
NEUROLOGY (2009)
Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study
D. Cadavid et al.
NEUROLOGY (2009)
Cortical lesions in primary progressive multiple sclerosis A 2-year longitudinal MR study
M. Calabrese et al.
NEUROLOGY (2009)
ADVANCED MAGNETIC RESONANCE IMAGING METRICS: IMPLICATIONS FOR MULTIPLE SCLEROSIS CLINICAL TRIALS
Robert Zivadinov
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2009)
Blockade of Glutamate Release from Microglia Attenuates Experimental Autoimmune Encephalomyelitis in Mice
Jin Shijie et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model
Ying Deng-Bryant et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2008)
Regional CNS responses to IFN-γ determine lesion localization patterns during EAE pathogenesis
Jason R. Lees et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis
Richard A. O'Connor et al.
JOURNAL OF IMMUNOLOGY (2008)
Autologous haematopoietic stem-cell transplantation in multiple sclerosis
Gianluigi Mancardi et al.
LANCET NEUROLOGY (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?
Re Gonsette
MULTIPLE SCLEROSIS JOURNAL (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice
Manik C. Ghosh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The immunology of multiple sclerosis
Amit Bar-Or
SEMINARS IN NEUROLOGY (2008)
Th17 Cells and Autoimmune Encephalomyelitis (EAE/MS)
Toshimasa Aranami et al.
ALLERGOLOGY INTERNATIONAL (2008)
Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology
Gerty Schreibelt et al.
BRAIN RESEARCH REVIEWS (2007)
An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment
Spencer C. Liang et al.
JOURNAL OF IMMUNOLOGY (2007)
The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis
Thomas Korn et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis
Massimiliano Calabrese et al.
ARCHIVES OF NEUROLOGY (2007)
Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis
Madhuri Bhasin et al.
BMC IMMUNOLOGY (2007)
Mouse model mimics multiple sclerosis in the clinico-radiological paradox
Jens Wuerfel et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis
Eugene D. Ponomarev et al.
JOURNAL OF IMMUNOLOGY (2007)
Involvement of TNF-α in glutamate-induced apoptosis in a differentiated neuronal cell line
Jiro Kogo et al.
BRAIN RESEARCH (2006)
Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system
Henrik Toft-Hansen et al.
JOURNAL OF IMMUNOLOGY (2006)
Neuroprotective effects of the stable nitroxide compound Tempol on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in the Nerve Growth Factor-differentiated model of pheochromocytoma PC12 cells
Tatiana Lipman et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
FOXP3+ regulatory T cells:: Current controversies and future perspectives
Alison H. Banham et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis
Xiaoping Qi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
L. Kappos et al.
NEUROLOGY (2006)
Neocortical neuronal, synaptic, and glial loss in multiple sclerosis
C. Wegner et al.
NEUROLOGY (2006)
Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis
J. T. Chen et al.
NEUROLOGY (2006)
Cortical demyelination in multiple sclerosis: A substrate for cognitive deficits?
Alexandra Kutzelnigg et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
Recovery from experimental allergic encephalomyelitis is TGF-β dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells
XM Zhang et al.
INTERNATIONAL IMMUNOLOGY (2006)
Restrictive and diversifying elements of the anti-myelin/oligodendrocyte glycoprotein antibody response in primate experimental allergic encephalomyelitis
HC von Büdingen et al.
IMMUNOGENETICS (2006)
The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion
MH Barnett et al.
MULTIPLE SCLEROSIS (2006)
Medical progress: Multiple sclerosis - The plaque and its pathogenesis
EM Frohman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study
W Rashid et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Antioxidants in multiple sclerosis - Do they have a role in therapy?
Noel G. Carlson et al.
CNS DRUGS (2006)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1
T Nguyen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Improvement of leukocyte functions in young prematurely aging mice after a 5-week ingestion of a diet supplemented with biscuits enriched in antioxidants
C Alvarado et al.
ANTIOXIDANTS & REDOX SIGNALING (2005)
Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice
R Verbeek et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis
S Camelo et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Mega-dose vitamin C modulates T cell functions in Balb/c mice only when administered during T cell activation
K Noh et al.
IMMUNOLOGY LETTERS (2005)
Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport
H Takeuchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes
C Moon et al.
BRAIN RESEARCH (2005)
Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant
Y Gilgun-Sherki et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2005)
Mitochondrial dysfunction plays a key role in progressive axonal loss in multiple sclerosis
HE Andrews et al.
MEDICAL HYPOTHESES (2005)
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis
B Serafini et al.
BRAIN PATHOLOGY (2004)
Dietary compounds prevent oxidative damage and nitric oxide production by cells involved in demyelinating disease
ME van Meeteren et al.
BIOCHEMICAL PHARMACOLOGY (2004)
α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis
M Morini et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte
G Muthian et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
Evidence for pathogenic heterogeneity in multiple sclerosis
CF Lucchinetti et al.
ANNALS OF NEUROLOGY (2004)
Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats
A Ilhan et al.
FREE RADICAL BIOLOGY AND MEDICINE (2004)
Tempol reduces the activation of nuclear factor-κB in acute inflammation
S Cuzzocrea et al.
FREE RADICAL RESEARCH (2004)
Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice
JA Quandt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Interferon beta-1b in secondary progressive MS - A combined analysis of the two trials
L Kappos et al.
NEUROLOGY (2004)
Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis
O Aktas et al.
JOURNAL OF IMMUNOLOGY (2004)
Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan
PH Larsen et al.
JOURNAL OF NEUROSCIENCE (2003)
Amino acid and protein oxidation in cardiovascular disease
ML Brennan et al.
AMINO ACIDS (2003)
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis
A Bar-Or et al.
BRAIN (2003)
Stable nitroxide Tempol ameliorates brain injury by inhibiting lipid peroxidation in a rat model of transient focal cerebral ischemia
N Kato et al.
BRAIN RESEARCH (2003)
Subpial demyelination in the cerebral cortex of multiple sclerosis patients
L Bo et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system
BA 't Hart et al.
CURRENT OPINION IN NEUROLOGY (2003)
Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis
YR Liu et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
Primary progressive multiple sclerosis: a 5-year clinical and MR study
GT Ingle et al.
BRAIN (2003)
Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation
C Thiemermann
CRITICAL CARE MEDICINE (2003)
Axonal degeneration and progressive neurologic disability in multiple sclerosis
C Bjartmar et al.
NEUROTOXICITY RESEARCH (2003)
Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis
X Zhang et al.
IMMUNOLOGIC RESEARCH (2003)
Oral interferon beta-1 alpha in relapsing-remitting multiple sclerosis: a double-blind randomized study
C Polman et al.
MULTIPLE SCLEROSIS (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial
H Panitch et al.
NEUROLOGY (2002)
Comparison of uric acid and ascorbic acid in protection against EAE
SV Spitsin et al.
FREE RADICAL BIOLOGY AND MEDICINE (2002)
Thalamic neurodegeneration in multiple sclerosis
A Cifelli et al.
ANNALS OF NEUROLOGY (2002)
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
T Kuhlmann et al.
BRAIN (2002)
Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine
C Paul et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions
JW Peterson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
Brain atrophy in clinically early relapsing-remitting multiple sclerosis
DT Chard et al.
BRAIN (2002)
Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis
YR Liu et al.
NEUROREPORT (2001)
Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro
A van der Goes et al.
FASEB JOURNAL (2001)
The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes
CG Schnackenberg et al.
KIDNEY INTERNATIONAL (2001)
Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat
S Cuzzocrea et al.
CRITICAL CARE MEDICINE (2001)
Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis
S Sathornsumetee et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Effects of tempol, a membrane-permeable radical scavenger, in a rodent model of carrageenan-induced pleurisy
S Cuzzocrea et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Autoimmune encephalomyelitis ameliorated by AMPA antagonists
T Smith et al.
NATURE MEDICINE (2000)
分享论文
